L&K Biomed Statistics

Total Valuation

L&K Biomed has a market cap or net worth of KRW 130.19 billion. The enterprise value is 127.18 billion.

Market Cap	130.19B
Enterprise Value	127.18B

Important Dates

The last earnings date was Wednesday, May 7, 2025.

Earnings Date	May 7, 2025
Ex-Dividend Date	n/a

Share Statistics

L&K Biomed has 19.94 million shares outstanding. The number of shares has increased by 32.67% in one year.

Current Share Class	19.94M
Shares Outstanding	19.94M
Shares Change (YoY)	+32.67%
Shares Change (QoQ)	+31.58%
Owned by Insiders (%)	13.27%
Owned by Institutions (%)	0.66%
Float	17.29M

Valuation Ratios

The trailing PE ratio is 14.57.

PE Ratio	14.57
Forward PE	n/a
PS Ratio	3.61
PB Ratio	3.61
P/TBV Ratio	3.14
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 23.77, with an EV/FCF ratio of -15.87.

EV / Earnings	13.05
EV / Sales	3.52
EV / EBITDA	23.77
EV / EBIT	45.78
EV / FCF	-15.87

Financial Position

The company has a current ratio of 1.63, with a Debt / Equity ratio of 0.65.

Current Ratio	1.63
Quick Ratio	0.90
Debt / Equity	0.65
Debt / EBITDA	4.14
Debt / FCF	-2.92
Interest Coverage	1.15

Financial Efficiency

Return on equity (ROE) is 27.47% and return on invested capital (ROIC) is 3.72%.

Return on Equity (ROE)	27.47%
Return on Assets (ROA)	2.64%
Return on Invested Capital (ROIC)	3.72%
Return on Capital Employed (ROCE)	7.00%
Revenue Per Employee	601.54M
Profits Per Employee	162.39M
Employee Count	60
Asset Turnover	0.50
Inventory Turnover	0.27

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -30.58% in the last 52 weeks. The beta is 2.03, so L&K Biomed's price volatility has been higher than the market average.

Beta (5Y)	2.03
52-Week Price Change	-30.58%
50-Day Moving Average	6,539.60
200-Day Moving Average	7,089.30
Relative Strength Index (RSI)	48.20
Average Volume (20 Days)	54,028

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, L&K Biomed had revenue of KRW 36.09 billion and earned 9.74 billion in profits. Earnings per share was 448.22.

Revenue	36.09B
Gross Profit	30.14B
Operating Income	3.08B
Pretax Income	9.82B
Net Income	9.74B
EBITDA	5.65B
EBIT	3.08B
Earnings Per Share (EPS)	448.22

Full Income Statement

Balance Sheet

The company has 19.94 billion in cash and 23.40 billion in debt, giving a net cash position of -3.45 billion or -173.23 per share.

Cash & Cash Equivalents	19.94B
Total Debt	23.40B
Net Cash	-3.45B
Net Cash Per Share	-173.23
Equity (Book Value)	36.03B
Book Value Per Share	2,131.56
Working Capital	24.49B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -7.43 billion and capital expenditures -584.84 million, giving a free cash flow of -8.02 billion.

Operating Cash Flow	-7.43B
Capital Expenditures	-584.84M
Free Cash Flow	-8.02B
FCF Per Share	-402.02

Full Cash Flow Statement

Margins

Gross margin is 83.51%, with operating and profit margins of 8.53% and 27.00%.

Gross Margin	83.51%
Operating Margin	8.53%
Pretax Margin	27.19%
Profit Margin	27.00%
EBITDA Margin	15.65%
EBIT Margin	8.53%
FCF Margin	n/a

Dividends & Yields

L&K Biomed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-32.67%
Shareholder Yield	-32.67%
Earnings Yield	7.48%
FCF Yield	-6.16%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

L&K Biomed has an Altman Z-Score of 1.99. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.99
Piotroski F-Score	n/a